Fig. 6: ZLDI-8 increases in vivo sensitization of Sorafenib in an intra-hepatic tumor model. | Cell Death & Disease

Fig. 6: ZLDI-8 increases in vivo sensitization of Sorafenib in an intra-hepatic tumor model.

From: Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells

Fig. 6

MHCC97-H cells were injected into the right lobe of the liver. Animals were received solvent control, ZLDI-8, Sorafenib or ZLDI-8+Sorafenib. Next, 18F-FDG/PET images (n = 5) were obtained (a) and the results of the PET were confirmed by the radioactivity of ablated livers (b). The PET imagines of ablated livers (b) and Masson staining (c) were also showed. The arrows indicate intrahepatic tumor nodules. *p < 0.05 vs. Sorafenib or control; *p < 0.05 vs. ZLDI-8 or control

Back to article page